Easier drug schedules help cognitively impaired HIV patients

December 23, 2002

LOS ANGELES -- In a study that used computerized pill bottles to track medication adherence, HIV-infected patients with cognitive problems were far more likely to miss doses when they had to take pills three times a day, compared to once or twice per day.

Reporting in the December 24 issue of Neurology, researchers at the Veterans Affairs Greater Los Angeles Health Care System and the University of California, Los Angeles, suggest simpler drug therapies may be critical in managing HIV, which often requires complex drug regimens of up to 20 to 30 pills per day.

The study of 137 of adults with HIV found that 34 percent had problems with memory, attention or decision-making--common symptoms of HIV infection. On average, these patients followed their drug regimen only 70 percent of the time over the one-month study period, compared to 82 percent for patients with no cognitive trouble.

Among the cognitively impaired group, medication adherence dropped to 52 percent when patients had to take three daily doses of their main HIV drug, compared to 78 percent for those who needed only one or two doses.

According to lead author Charles H. Hinkin, PhD, there is likely a two-way relationship between missed doses and disease progression, resulting in a downward spiral for HIV patients. Drugs that fight the spread of HIV in the body also protect the mind. Those who miss doses are likely to suffer more effects of the infection, including memory and attention problems, resulting in poorer adherence to the drug regimen.

"Those who fail to take their medications are more likely to develop cognitive problems that in turn further compromise their adherence," said Hinkin, a neuropsychologist with VA and UCLA.

Patients in the study were all on highly active antiretroviral therapy (HAART), which can involve "cocktails" of up to four or five medications. The therapy can fail when patients do not take all their prescribed doses, resulting in worse symptoms and the development of drug-resistant strains of the virus, which can then be transmitted to others.

A study at the VA Pittsburgh Health Care System, published in the Annals of Internal Medicine in 2000, showed that HAART failed to suppress the virus in only 1 of 5 patients who took their medications 95 percent of the time. The figure climbed to 4 of 5 patients for those with poorer than 80 percent adherence. Patients with poorer adherence had more opportunistic infections and spent more days in the hospital.

Hinkin's study used pill bottles with computer chips that recorded when the bottle was opened. He said this posed an advantage over previous studies of HAART adherence that relied on pill counts by medical staff or self-reports from patients. Both those methods are thought to underestimate non-adherence. Another strength of the study, said Hinkin, is that it used extensive neuropsychological tests, rather than patients' own reports of their cognitive ability.

One surprising finding in the study: Participants over age 50 were nearly three more likely than younger patients to stick to their medication schedule. Hinkin explained that older adults may be more accustomed to taking medications, or their daily routines may be better suited to it. Also, none of the patients in the study were age 70 or older, when cognitive decline becomes more of an issue. However, in a related study, the VA/UCLA team found that older HIV patients who were cognitively impaired had the greatest degree of difficulty with medication adherence.

Hinkin's group is conducting further research on the relationship between cognitive status and HAART adherence, as well as exploring other factors known to disrupt drug regimens, such as alcoholism, drug abuse and depression.
-end-
The study was funded by the National Institute of Mental Health and the National Institute on Drug Abuse.

NOTE FOR REPORTERS: Charles H. Hinkin, Ph.D., is the lead author for this study. For interviews, please contact Beverly Fitzgerald, VA Greater Los Angeles Care System, at 310-268-3340 or Beverly.Fitzgerald@med.va.gov. For additional assistance, contact Dave Bayard, VA Office of Public Affairs, at 310-268-4207 or dave.bayard@mail.va.gov.

For Information Contact:

Beverly Fitzgerald
310-268-3340
Beverly.Fitzgerald@med.va.gov

Dave Bayard
310-268-4207
dave.bayard@mail.va.gov

Veterans Affairs Research Communications

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.